EVALUATION OF DEMOGRAPHIC, CLINIC AND GENETIC CHARACTERISTICS OF PATIENTS ADMITTED TO TRAKYA UNIVERSITY HOSPITAL WITH HYPERTROPHIC CARDIOMYOPATHY

Year 2021, Volume: 8 Issue: 3, 119 - 122, 01.10.2021

Burak Bardakçı , Berfin Tan Sarper Kızılkaya Ceren Yüksel Servet Altay

Abstract

Aims: This study aims to evaluate the genetics, clinical characteristics, and functional abnormalities of patients diagnosed with hypertrophic cardiomyopathy in Trakya University Hospital. Methods: This retrospective study was conducted with patients who were diagnosed with hypertrophic cardiomyopathy between November 2009 - November 2019 in Trakya University Hospital. The data were obtained from the hospital’s database. Patients’ data (regarding age, gender, ge- netics, transthoracic echocardiogram findings, medications, types of hypertrophic cardiomyopathy, and first diagnoses) were examined. Numbers, percentages, means, and standard deviations were used as descriptive statistics. Results: Eleven patients with hypertrophic cardiomyopathy were evaluated. Five (45.45%) were female and 6 (54.54%) were male. The mean age of the female patients was 58.20 ± 8.57 years. The most common type of hypertrophic cardiomyopathy was found to be asymmetrical septal cardiomyopathy [7 (63.63%)]. Three (27.27%) patients presented with hypertension. There were gene mutations in three patients. Among these three patients, two (18.18%) patients have MYBPC3, and one (9.09%) patient has TTN gene mutations. Conclusion: Hypertrophic car- diomyopathy is usually accompanied by comorbidities such as arrhythmias, myocardial infarction, coronary artery disease. Therefore, these patients must be paid attention to in these matters.

Keywords

Hypertrophic cardiomyopathy, hypertension, sudden cardiac death

References

• 1. Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón JP et al. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet 2018;93(1):3- 14.
• 2. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013;381(9862):242- 55.
• 3. Cruickshank S. Cardiomyopathy. Nurs Stand 2004;18(23):46-56.
• 4. Teekakirikul P, Zhu W, Huang HC et al. Hypertrophic cardiomyopathy: an over- view of genetics and management. Biomolecules 2019;9(12):878.
• 5. Wigle ED, The diagnosis of hypertrohic cardiomyopatyh. Heart 2001;86(6):709- 14.
• 6. Hensley N, Dietrich J, Nyhan D et al. M. Hypertrophic cardiomyopathy: a review. Anesth Analg 2015;120(3):554-69.
• 7. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121(7):749-70.
• 8. Shah M. Hypertrophic cardiomyopathy. Cardiol Young 2017;27(S1):25-30.
• 9. Noureldin RA, Liu S, Nacif MS et al. The diagnosis of hypertrophic cardio- myopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14(1):17.
• 10. van Velzen HG, Schinkel AFL, Baart SJ et al. Effect of gender and genetic muta- tions on outcomes in patients with hypertrophic cardiomyopathy. Am J Cardiol 2018;122(11):1947-54.
• 11. Olivotto I, Maron MS, Adabag AS et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46(3):480-7.
• 12. Brown NJ, Vaughan DE. Angiotensin converting enzyme inhibitors. Circulation 1990;97(14):1411-20.
• 13. Cordonnier DJ, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabe- tes mellitus. Drugs 2001;61(13):1883-92.
• 14. Deng T, Ou B, Zhu T et al. The effect of hypertension on cardiac structure and function in different types of hypertrophic cardiomyopathy: a single-center retro- spective study. Clin Exp Hypertens 2019;41(4):359-65.
• 15. Papadopoulos DP, Papademetriou V. Hypertrophic and hypertensive hypertro- phic cardiomyopathy--a true association? Angiology 2010;61(1):92-9.
• 16. Teenkakirikul P, Zhu W, Huang HC et al. Hypertrophic cardiomyopathy; an over- view of genetics and management. Biomolecules 2019;19(9):878.
• 17. Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagno- sis strategy. Circulation 2003;107(17):2227-32.
• 18. Yacoub MH, El-Hamamsy I, Said K et al. The left ventricular outflow in hyper- trophic cardiomyopathy: from structure to function. J Cardiovasc Transl Res 2009;2(4):510-7.
• 19. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348(4):295-303.
• 20. Lee MS, Chen CH. Myocardial bridging: an up-to-date review. J Invasive Cardiol 2015;27(11):521-8.
• 21. Raphael CE, Cooper R, Parker KH et al. Mechanism of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnet- ic resonance. J Am Coll Cardiol 2016;68(15):1651-60.
• 22. Maclntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2016;133(19):1901-5.